您的购物车当前为空
Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.

Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 待询 |
| 产品描述 | Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities. |
| 分子量 | 2293.78 |
| 分子式 | C96H177N39O24S |
| CAS No. | 1164096-85-8 |
| 密度 | no data available |
| Sequence Short | ATRAGLQVRKNKRRRGCPIL |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容